PALB2 Gene Mutation: Cancer Risk, Screening, and Next Steps

PALB2 stands for Partner And Localizer of BRCA2. It is a gene that produces a protein essential for repairing serious DNA damage in your cells. The PALB2 protein works in direct partnership with the BRCA2 protein — it physically binds to BRCA2 and brings it to the site of DNA double-strand breaks so that repairs can begin. Without functional PALB2, the BRCA2 repair system cannot work properly, even if the BRCA2 gene itself is completely normal.

PALB2 is often described as the “missing link” in the DNA repair pathway because it connects BRCA1 and BRCA2. BRCA1 detects DNA damage, PALB2 recruits BRCA2 to the damage site, and BRCA2 carries out the repair. A mutation in any one of these three genes disrupts the entire pathway, which is why PALB2 carriers face cancer risks similar to those seen in BRCA carriers.

PALB2 mutations are inherited in an autosomal dominant pattern, meaning you only need one copy of the mutated gene (from one parent) for it to affect your cancer risk. Approximately 1 in 1,000 people in the general population carry a PALB2 mutation. PALB2 is classified as a high-to-moderate risk gene — its breast cancer risk is higher than moderate-risk genes like CHEK2 and ATM, but somewhat lower than BRCA1. For an overview of how hereditary cancer genes are identified and tested, see our guide on hereditary cancer screening.

A PALB2 mutation meaningfully raises your risk for several cancers. Recent research has upgraded PALB2’s risk classification, and NCCN now recommends enhanced screening similar to BRCA management. Here is how PALB2 cancer risks compare to the general population:

Breast cancer (women)

• General population lifetime risk: approximately 13%
• PALB2 mutation carriers: approximately 35–58% lifetime risk
• Risk varies significantly based on family history — women with a strong family history of breast cancer may face risk approaching BRCA2 levels
• PALB2 is now recognized as one of the most significant hereditary breast cancer genes outside of BRCA1 and BRCA2

Ovarian cancer

• General population lifetime risk: approximately 1–2%
• PALB2 carriers: modestly elevated, approximately 3–5%
• This elevation is less established than the breast cancer association and substantially lower than ovarian cancer risk from BRCA mutations

Pancreatic cancer

• General population lifetime risk: approximately 0.5%
• PALB2 carriers: approximately 2–3% lifetime risk
• The absolute risk remains relatively low, but the relative increase is meaningful, particularly for carriers with a family history of pancreatic cancer

Male breast cancer

• General population lifetime risk: approximately 0.1%
• PALB2 carriers: elevated to approximately 1%
• While still uncommon, male PALB2 carriers should be aware of this increased risk

Key takeaway: PALB2 is emerging as one of the more significant hereditary breast cancer genes. Recent studies have upgraded its risk classification closer to BRCA2. Enhanced screening is strongly recommended for all PALB2 carriers.

PALB2 and BRCA are closely related — they work together in the same DNA repair pathway. Understanding the differences helps put a PALB2 result in proper context.

• Functional relationship: PALB2 physically connects BRCA1 and BRCA2 in the DNA repair process. A mutation in any of these three genes disrupts the same pathway, which is why their cancer risks overlap.
• Breast cancer risk: BRCA1 carries an approximately 50–72% lifetime breast cancer risk. BRCA2 carries approximately 45–69%. PALB2 carries approximately 35–58%. PALB2 risk is lower overall but can approach BRCA2 levels in women with strong family histories.
• Ovarian cancer: BRCA1 (~44% lifetime risk) and BRCA2 (~17%) carry substantially higher ovarian cancer risk than PALB2 (~3–5%). This difference is important for surgical decision-making.
• Pancreatic cancer: PALB2 and BRCA2 carry similar modest elevations in pancreatic cancer risk (approximately 2–3% lifetime).
• Screening approach: PALB2 screening recommendations have become more aggressive in recent guidelines and are now closer to BRCA2 protocols. Annual breast MRI plus mammogram starting at age 30 is recommended for PALB2 carriers.
• Risk-reducing surgery: Risk-reducing mastectomy is discussed for PALB2 carriers, similar to BRCA. However, risk-reducing oophorectomy is not routinely recommended for PALB2 carriers given the lower ovarian cancer risk.

All three genes are included in standard multi-gene panel tests. If you previously had BRCA-only testing, discuss updated panel testing with your provider — it now includes PALB2 and other important genes.

NCCN guidelines now recommend enhanced screening for PALB2 carriers that closely mirrors BRCA management. Your provider may adjust these recommendations based on your personal and family history.

Women with a PALB2 mutation

• Annual breast MRI starting at age 30
• Annual mammogram starting at age 30
• Clinical breast exam every 6–12 months
• Discussion of risk-reducing mastectomy, particularly with a strong family history of breast cancer
• Risk-reducing salpingo-oophorectomy (RRSO) is not routinely recommended given the lower ovarian cancer risk compared to BRCA carriers — discuss with your provider on an individual basis

Men with a PALB2 mutation

• Monthly breast self-awareness and self-exam
• Annual clinical breast exam starting at age 35
• Discuss prostate cancer screening with your doctor based on family history
• Discuss pancreatic cancer surveillance if there is a family history of pancreatic cancer

All PALB2 carriers

• Cascade testing: first-degree relatives (parents, siblings, children) should be offered genetic testing
• Discuss pancreatic cancer surveillance if there is a family history of pancreatic cancer
• Keep your healthcare team informed about your PALB2 status so they can tailor your care

Important: Screening recommendations vary based on your personal and family history. Other moderate-to-high risk genes like ATM and CHEK2 have different screening schedules. A licensed genetic counselor can help you build a personalized screening plan based on your specific mutation and risk profile.

If you are reading about PALB2, you may come across references to Fanconi anemia — a rare genetic condition that affects bone marrow function and increases cancer risk in children. Understanding the connection between PALB2 and Fanconi anemia can help reduce unnecessary worry.

Fanconi anemia is caused by inheriting two mutated copies (one from each parent) of certain DNA repair genes, including PALB2. This is called biallelic inheritance. When a child inherits two PALB2 mutations, the DNA repair pathway is completely nonfunctional, which causes the serious symptoms of Fanconi anemia.

A single PALB2 mutation — the type identified through hereditary cancer genetic testing — does not cause Fanconi anemia. Carriers have one working copy and one mutated copy of the gene. The working copy provides enough PALB2 protein to prevent Fanconi anemia, though the reduced repair capacity does increase cancer risk over a lifetime.

The Fanconi anemia connection becomes relevant for family planning. If both parents carry a PALB2 mutation, each child has a 25% chance of inheriting two mutated copies and developing Fanconi anemia. This is uncommon because PALB2 mutations are rare (approximately 1 in 1,000 people), but it is a reason why genetic counseling can be valuable for PALB2 carriers who are planning a family.

If you are a PALB2 carrier and your partner has not been tested, a genetic counselor can discuss whether partner testing is appropriate based on your family histories and reproductive plans.

If you have received a positive PALB2 genetic test result, here are the steps to take:

1. Inform your gynecologist or primary care doctor. Your PALB2 status directly changes your recommended screening schedule. Your provider should update your care plan to include annual breast MRI and mammogram starting at age 30, along with other surveillance measures.
2. See a genetic counselor. PALB2 cancer risk varies significantly based on your family history and the specific mutation you carry. A licensed genetic counselor can interpret your result in the context of your personal and family history and create a personalized risk management plan. For guidance on finding the right counselor, see our resource on genetic counseling for cancer.
3. Tell your first-degree relatives. Each parent, sibling, and child of a PALB2 carrier has a 50% chance of carrying the same mutation. Sharing your result gives family members the opportunity to get tested and begin appropriate screening if needed. Our guide on cascade testing for families explains how to approach these conversations.
4. Begin annual breast MRI and mammogram starting at age 30. If you are already over 30, schedule these screenings as soon as possible. Early detection is the most effective tool for PALB2 carriers.
5. Discuss pancreatic cancer surveillance if you have a family history. PALB2 elevates pancreatic cancer risk, and surveillance may be appropriate if pancreatic cancer has occurred in your family.

For general guidance on interpreting different types of genetic test results, see our resource on understanding your genetic test results. If you have not been tested yet and want to find out whether hereditary cancer genetic testing is right for you, our free eligibility screener can help.

Ready to find out if you qualify? Learn more about BRCA and hereditary cancer panel testing.

NCCN recommends PALB2 genetic testing as part of multi-gene panel testing for individuals who meet hereditary breast and ovarian cancer testing criteria. This includes personal or family history of early-onset breast cancer, multiple breast cancers, ovarian cancer, pancreatic cancer, or a known PALB2 mutation in the family.

PALB2 follows autosomal dominant inheritance, so each first-degree relative of a carrier has a 50% chance of also carrying the mutation. Because PALB2 is now recognized as a high-risk breast cancer gene, NCCN recommends offering cascade testing to all blood relatives. Identifying carriers early allows them to start enhanced screening and consider risk-reduction options before cancer develops.